J. Matthew Singleton
CIK: 0001243514
Associated companies
Transaction History
| VKTX | ▲ Buy | Grant | 3,150 | $0 | 1/2/2026 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 16,000 | $72K | 10/25/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 16,000 | $1.3M | 10/25/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 10,300 | $12K | 9/20/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 10,300 | $716K | 9/20/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 5,700 | $7K | 8/21/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 5,700 | $397K | 8/21/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 16,000 | $53K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 2,500 | $150K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 2,055 | $130K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 3,047 | $186K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 4,509 | $279K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 1,501 | $97K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 2,388 | $153K | 8/19/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 20,626 | $1.2M | 8/14/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 20,786 | $166K | 8/14/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 160 | $9K | 8/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.